Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

preview_player
Показать описание
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on the role of checkpoint inhibitors in the treatment of multiple myeloma (MM)
  1. OBRoncology
Рекомендации по теме
Sundar Jagannath, MD, 0:01:46

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

Sundar Jagannath, MD, 0:02:09

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

Dr. Sundar Jagannath 0:01:19

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

Sundar Jagannath, MD, 0:02:56

Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM

Dr. Sundar Jagannath 0:01:06

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

Managing the challenges 0:01:30

Managing the challenges associated with continuous BCMA-directed therapy in multiple myeloma

Dr. Jagannath on 0:01:54

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Dr. Jagannath Discusses 0:02:02

Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma

Sundar Jagannath, MD, 0:02:57

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

Sundar Jagannath, MD, 0:01:27

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

Dr. Jagannath on 0:01:26

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Sundar Jagannath, MD, 0:03:00

Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM

Sundar Jagannath, MD, 0:01:16

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

COVID19 Updates for 0:11:08

COVID19 Updates for the Myeloma Patient - Sundar Jagannath

Dr. Jagannath on 0:01:54

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Sundar Jagannath, MD, 0:03:23

Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients

Dr. Jagannath on 0:01:24

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

Dr. Jagannath on 0:02:12

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

Biochemical Versus Symptomatic 0:05:05

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Dr. Jagannath on 0:01:21

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Dr. Jagannath on 0:02:04

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Multiple Myeloma Regimens 0:06:03

Multiple Myeloma Regimens

Connect® MM: treatment 0:12:08

Connect® MM: treatment patterns and holistic burden in triple-class refractory multiple myeloma

Maintenance Therapy Improves 0:04:57

Maintenance Therapy Improves Outcomes in Multiple Myeloma